Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 7
2004 5
2005 4
2006 6
2007 6
2008 5
2009 3
2010 2
2011 2
2012 4
2013 11
2014 6
2015 6
2016 11
2017 21
2018 20
2019 8
2020 26
2021 29
2022 25
2023 30
2024 37
2025 43
2026 30

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

314 results

Results by year

Filters applied: . Clear all
Page 1
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy.
Mountzios G, Sun L, Cho BC, Demirci U, Baka S, Gümüş M, Lugini A, Zhu B, Yu Y, Korantzis I, Han JY, Ciuleanu TE, Ahn MJ, Rocha P, Mazières J, Lau SCM, Schuler M, Blackhall F, Yoshida T, Owonikoko TK, Paz-Ares L, Jiang T, Hamidi A, Gauto D, Recondo G, Rudin CM; DeLLphi-304 Investigators. Mountzios G, et al. Among authors: yoshida t. N Engl J Med. 2025 Jul 24;393(4):349-361. doi: 10.1056/NEJMoa2502099. Epub 2025 Jun 2. N Engl J Med. 2025. PMID: 40454646 Clinical Trial.
Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study.
Paz-Ares L, Champiat S, Lai WV, Izumi H, Govindan R, Boyer M, Hummel HD, Borghaei H, Johnson ML, Steeghs N, Blackhall F, Dowlati A, Reguart N, Yoshida T, He K, Gadgeel SM, Felip E, Zhang Y, Pati A, Minocha M, Mukherjee S, Goldrick A, Nagorsen D, Hashemi Sadraei N, Owonikoko TK. Paz-Ares L, et al. Among authors: yoshida t. J Clin Oncol. 2023 Jun 1;41(16):2893-2903. doi: 10.1200/JCO.22.02823. Epub 2023 Jan 23. J Clin Oncol. 2023. PMID: 36689692 Free PMC article. Clinical Trial.
Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments.
Kumagai S, Koyama S, Itahashi K, Tanegashima T, Lin YT, Togashi Y, Kamada T, Irie T, Okumura G, Kono H, Ito D, Fujii R, Watanabe S, Sai A, Fukuoka S, Sugiyama E, Watanabe G, Owari T, Nishinakamura H, Sugiyama D, Maeda Y, Kawazoe A, Yukami H, Chida K, Ohara Y, Yoshida T, Shinno Y, Takeyasu Y, Shirasawa M, Nakama K, Aokage K, Suzuki J, Ishii G, Kuwata T, Sakamoto N, Kawazu M, Ueno T, Mori T, Yamazaki N, Tsuboi M, Yatabe Y, Kinoshita T, Doi T, Shitara K, Mano H, Nishikawa H. Kumagai S, et al. Among authors: yoshida t. Cancer Cell. 2022 Feb 14;40(2):201-218.e9. doi: 10.1016/j.ccell.2022.01.001. Epub 2022 Jan 28. Cancer Cell. 2022. PMID: 35090594 Free article.
Sustained Clinical Benefit and Intracranial Activity of Tarlatamab in Previously Treated Small Cell Lung Cancer: DeLLphi-300 Trial Update.
Dowlati A, Hummel HD, Champiat S, Olmedo ME, Boyer M, He K, Steeghs N, Izumi H, Johnson ML, Yoshida T, Bouchaab H, Borghaei H, Felip E, Jost PJ, Gadgeel S, Chen X, Yu Y, Martinez P, Parkes A, Paz-Ares L. Dowlati A, et al. Among authors: yoshida t. J Clin Oncol. 2024 Oct 10;42(29):3392-3399. doi: 10.1200/JCO.24.00553. Epub 2024 Aug 29. J Clin Oncol. 2024. PMID: 39208379 Free PMC article. Clinical Trial.
Genomic Profiles of Pathogenic and Moderate-Penetrance Germline Variants Associated With Risk of Early-Onset Lung Adenocarcinoma.
Cho H, Shiraishi K, Sunami K, Momozawa Y, Yoshida T, Matsumoto S, Matsuda K, Saito M, Goto A, Honda T, Mochizuki A, Torasawa M, Daigo Y, Shimizu K, Kunitoh H, Yoshida Y, Hirata M, Shimada Y, Ueki M, Ono H, Gotoh M, Shimoda Igawa Y, Tateishi A, Yamaguchi Y, Inaba Higashiyama R, Machida E, Iwasaki M, Kawai Y, Yasuda H, Hamamoto J, Imoto I, Matsushita H, Takata S, Aoi T, Kaneko S, Kuchiba A, Shimomura A, Fukami M, Hattori K, Ozaki K, Asano Y; NCBN Controls WGS Consortium; Biobank Japan Project; Takano A, Kobayashi M, Miyagi Y, Tanaka K, Suzuki H, Yamaura T, Yoshida T, Goto Y, Horinouchi H, Miyazaki Y, Ito H, Nagashima T, Ohtaki Y, Imai K, Minamiya Y, Okubo K, Inazawa J, Shiraishi Y, Tokunaga K, Kamatani Y, Yatabe Y, Goto K, Tsuboi M, Watanabe SI, Ohe Y, Murakami Y, Matsuo K, Hamamoto R, Kohno T. Cho H, et al. Among authors: yoshida t. J Thorac Oncol. 2025 Nov;20(11):1626-1638. doi: 10.1016/j.jtho.2025.06.005. Epub 2025 Jun 15. J Thorac Oncol. 2025. PMID: 40516820 Free article.
First-line nivolumab plus platinum chemotherapy and bevacizumab for advanced nonsquamous non-small cell lung cancer: A 3-year follow-up of the phase 3 randomized TASUKI-52 trial.
Lee KH, Lee JS, Sugawara S, Kang JH, Kim HR, Inui N, Hida T, Yoshida T, Tanaka H, Yang CT, Inoue T, Nishio M, Ohe Y, Tamura T, Yamamoto N, Yu CJ, Akamatsu H, Takahashi S, Nakagawa K. Lee KH, et al. Among authors: yoshida t. Lung Cancer. 2025 Mar;201:108109. doi: 10.1016/j.lungcan.2025.108109. Epub 2025 Jan 25. Lung Cancer. 2025. PMID: 39893774 Free article. Clinical Trial.
An ATR-PrimPol pathway confers tolerance to oncogenic KRAS-induced and heterochromatin-associated replication stress.
Igarashi T, Mazevet M, Yasuhara T, Yano K, Mochizuki A, Nishino M, Yoshida T, Yoshida Y, Takamatsu N, Yoshimi A, Shiraishi K, Horinouchi H, Kohno T, Hamamoto R, Adachi J, Zou L, Shiotani B. Igarashi T, et al. Among authors: yoshida t. Nat Commun. 2023 Aug 17;14(1):4991. doi: 10.1038/s41467-023-40578-2. Nat Commun. 2023. PMID: 37591859 Free PMC article.
Urocortin2 measurement for heart failure assessment.
Inukai K, Miyashita K, Kotani K, Morimoto R, Kondo T, Hiraiwa H, Kazama S, Yoshida T, Yoshida S, Hattori T, Fukamachi K, Fukui N, Kato K, Yura Y, Ohashi K, Ouchi N, Murohara T, Okumura T, Takefuji M. Inukai K, et al. Among authors: yoshida t. Sci Rep. 2025 Apr 24;15(1):14381. doi: 10.1038/s41598-025-99509-4. Sci Rep. 2025. PMID: 40275076 Free PMC article.
Mutation of CMTR2 in Lung Adenocarcinoma Alters RNA Alternative Splicing and Reveals Therapeutic Vulnerabilities.
Nukaga S, Shiraishi K, Hamabe K, Mochizuki A, Hamaguchi Y, Ogawa E, Le NT, Shimada Y, Ono H, Nishinakamura H, Kobayashi Y, Hamamoto J, Ui A, Araki M, Sagae Y, Ohgino K, Sugihara K, Endo S, Miyakoshi J, Shiraishi Y, Yasuda H, Okuno Y, Yoshida T, Goto Y, Ohe Y, Watanabe SI, Yatabe Y, Nishikawa H, Hamamoto R, Kohno T, Nakaoku T. Nukaga S, et al. Among authors: yoshida t. Nat Commun. 2025 Nov 6;16(1):9754. doi: 10.1038/s41467-025-64821-0. Nat Commun. 2025. PMID: 41198678 Free PMC article.
314 results